Ad
related to: fda approved products 2024 2021
Search results
Results From The WOW.Com Content Network
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
In April 2018, guselkumab was approved in Japan for the treatment of psoriatic arthritis. [19] In July 2020, the FDA approved guselkumab as the first IL-23 inhibitor to treat active psoriatic arthritis (PsA). [20] [21] In September 2024, the FDA approved guselkumab for the treatment of moderately to severely active ulcerative colitis in adults. [9]
In January 2023, the US Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. [19] In March 2024, FDA granted accelerated approval to zanubrutinib, in combination with obinutuzumab, for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. [20] [21]
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.
In June 2024, the US FDA granted accelerated approval to adagrasib plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. [10] [11]
Sotatercept was approved for medical use in the United States in March 2024, [6] [11] [12] and in the European Union in August 2024. [ 7 ] [ 8 ] [ 13 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .
The FDA granted the approval of Lutathera to Advanced Accelerator Applications. [ 6 ] In April 2024, the FDA approved 177 Lu dotatate for the treatment of children aged 12 years and older with somatostatin receptor-positive (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut ...
Ad
related to: fda approved products 2024 2021mastercontrol.com has been visited by 10K+ users in the past month